These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
260 related articles for article (PubMed ID: 23186533)
1. Recurrent CEP85L-PDGFRB fusion in patient with t(5;6) and imatinib-responsive myeloproliferative neoplasm with eosinophilia. Winkelmann N; Hidalgo-Curtis C; Waghorn K; Score J; Dickinson H; Jack A; Ali S; Cross NC Leuk Lymphoma; 2013 Jul; 54(7):1527-31. PubMed ID: 23186533 [TBL] [Abstract][Full Text] [Related]
2. Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders. David M; Cross NC; Burgstaller S; Chase A; Curtis C; Dang R; Gardembas M; Goldman JM; Grand F; Hughes G; Huguet F; Lavender L; McArthur GA; Mahon FX; Massimini G; Melo J; Rousselot P; Russell-Jones RJ; Seymour JF; Smith G; Stark A; Waghorn K; Nikolova Z; Apperley JF Blood; 2007 Jan; 109(1):61-4. PubMed ID: 16960151 [TBL] [Abstract][Full Text] [Related]
3. Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms. Gosenca D; Kellert B; Metzgeroth G; Haferlach C; Fabarius A; Schwaab J; Kneba M; Scheid C; Töpelt K; Erben P; Haferlach T; Cross NC; Hofmann WK; Seifarth W; Reiter A Genes Chromosomes Cancer; 2014 May; 53(5):411-21. PubMed ID: 24772479 [TBL] [Abstract][Full Text] [Related]
4. NIN, a gene encoding a CEP110-like centrosomal protein, is fused to PDGFRB in a patient with a t(5;14)(q33;q24) and an imatinib-responsive myeloproliferative disorder. Vizmanos JL; Novo FJ; Román JP; Baxter EJ; Lahortiga I; Larráyoz MJ; Odero MD; Giraldo P; Calasanz MJ; Cross NC Cancer Res; 2004 Apr; 64(8):2673-6. PubMed ID: 15087377 [TBL] [Abstract][Full Text] [Related]
5. Characterization of three new imatinib-responsive fusion genes in chronic myeloproliferative disorders generated by disruption of the platelet-derived growth factor receptor beta gene. Walz C; Metzgeroth G; Haferlach C; Schmitt-Graeff A; Fabarius A; Hagen V; Prümmer O; Rauh S; Hehlmann R; Hochhaus A; Cross NC; Reiter A Haematologica; 2007 Feb; 92(2):163-9. PubMed ID: 17296564 [TBL] [Abstract][Full Text] [Related]
6. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. Apperley JF; Gardembas M; Melo JV; Russell-Jones R; Bain BJ; Baxter EJ; Chase A; Chessells JM; Colombat M; Dearden CE; Dimitrijevic S; Mahon FX; Marin D; Nikolova Z; Olavarria E; Silberman S; Schultheis B; Cross NC; Goldman JM N Engl J Med; 2002 Aug; 347(7):481-7. PubMed ID: 12181402 [TBL] [Abstract][Full Text] [Related]
7. Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms. Naumann N; Schwaab J; Metzgeroth G; Jawhar M; Haferlach C; Göhring G; Schlegelberger B; Dietz CT; Schnittger S; Lotfi S; Gärtner M; Dang TA; Hofmann WK; Cross NC; Reiter A; Fabarius A Genes Chromosomes Cancer; 2015 Dec; 54(12):762-70. PubMed ID: 26355392 [TBL] [Abstract][Full Text] [Related]
8. p53-Binding protein 1 is fused to the platelet-derived growth factor receptor beta in a patient with a t(5;15)(q33;q22) and an imatinib-responsive eosinophilic myeloproliferative disorder. Grand FH; Burgstaller S; Kühr T; Baxter EJ; Webersinke G; Thaler J; Chase AJ; Cross NC Cancer Res; 2004 Oct; 64(20):7216-9. PubMed ID: 15492236 [TBL] [Abstract][Full Text] [Related]
9. Novel t(5;11)(q32;q13.4) with NUMA1-PDGFRB fusion in a myeloid neoplasm with eosinophilia with response to imatinib mesylate. Zou YS; Hoppman NL; Singh ZN; Sawhney S; Kotiah SD; Baer MR Cancer Genet; 2017 Apr; 212-213():38-44. PubMed ID: 28449810 [TBL] [Abstract][Full Text] [Related]
10. Sustained Response to Imatinib in a Pediatric Patient with Concurrent Myeloproliferative Disease and Lymphoblastic Lymphoma Associated with a CCDC88C-PDGFRB Fusion Gene. Bielorai B; Leitner M; Goldstein G; Mehrian-Shai R; Trakhtenbrot L; Fisher T; Marcu V; Yalon M; Schiby G; Barel O; Cal N; Golan H; Toren A Acta Haematol; 2019; 141(2):119-127. PubMed ID: 30726835 [TBL] [Abstract][Full Text] [Related]
11. Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis. Erben P; Gosenca D; Müller MC; Reinhard J; Score J; Del Valle F; Walz C; Mix J; Metzgeroth G; Ernst T; Haferlach C; Cross NC; Hochhaus A; Reiter A Haematologica; 2010 May; 95(5):738-44. PubMed ID: 20107158 [TBL] [Abstract][Full Text] [Related]
12. KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia. Medves S; Duhoux FP; Ferrant A; Toffalini F; Ameye G; Libouton JM; Poirel HA; Demoulin JB Leukemia; 2010 May; 24(5):1052-5. PubMed ID: 20164854 [No Abstract] [Full Text] [Related]
13. [The efficacy of imatinib mesylate for patients with myeloproliferative neoplasm (MPN) with eosinophilia]. Zhang Y; Qin TJ; Zhou CL; Liu L; Xiao ZJ Zhonghua Xue Ye Xue Za Zhi; 2009 Jun; 30(6):381-4. PubMed ID: 19951530 [TBL] [Abstract][Full Text] [Related]
14. Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review. Savage N; George TI; Gotlib J Int J Lab Hematol; 2013 Oct; 35(5):491-500. PubMed ID: 23489324 [TBL] [Abstract][Full Text] [Related]
15. KIAA1509 is a novel PDGFRB fusion partner in imatinib-responsive myeloproliferative disease associated with a t(5;14)(q33;q32). Levine RL; Wadleigh M; Sternberg DW; Wlodarska I; Galinsky I; Stone RM; DeAngelo DJ; Gilliland DG; Cools J Leukemia; 2005 Jan; 19(1):27-30. PubMed ID: 15496975 [TBL] [Abstract][Full Text] [Related]
16. Fusion of PDGFRB to two distinct loci at 3p21 and a third at 12q13 in imatinib-responsive myeloproliferative neoplasms. Hidalgo-Curtis C; Apperley JF; Stark A; Jeng M; Gotlib J; Chase A; Cross NC; Grand FH Br J Haematol; 2010 Jan; 148(2):268-73. PubMed ID: 20085582 [TBL] [Abstract][Full Text] [Related]
17. Identification of a MYO18A-PDGFRB fusion gene in an eosinophilia-associated atypical myeloproliferative neoplasm with a t(5;17)(q33-34;q11.2). Walz C; Haferlach C; Hänel A; Metzgeroth G; Erben P; Gosenca D; Hochhaus A; Cross NC; Reiter A Genes Chromosomes Cancer; 2009 Feb; 48(2):179-83. PubMed ID: 19006078 [TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative neoplasm with eosinophilia and coexisting BCR::ABL1 and PDGFRB rearrangement: favorable and rapid response to imatinib. Yao S; Na L; Liangding H Ann Hematol; 2024 Aug; 103(8):3247-3250. PubMed ID: 38888615 [TBL] [Abstract][Full Text] [Related]
19. Identification of a Novel CSNK2A1-PDGFRB Fusion Gene in a Patient with Myeloid Neoplasm with Eosinophilia. Xu X; Lu Q; Wang Z; Cai P; Zeng Z; Zhang L; Wang M; Ma L; Ruan C; Chen S Cancer Res Treat; 2021 Jul; 53(3):889-892. PubMed ID: 33421986 [TBL] [Abstract][Full Text] [Related]
20. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders. Gallagher G; Horsman DE; Tsang P; Forrest DL Cancer Genet Cytogenet; 2008 Feb; 181(1):46-51. PubMed ID: 18262053 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]